Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255833 | 0.80 | CYP3A4 (0.47) | LMNAMEN1PABPC1KMT2ACYP3A4 | |
| SCHEMBL24420477 | 0.79 | ALDH1A1 (0.37) | LMNAMEN1PABPC1KMT2ACYP3A4 | |
| SCHEMBL28660913 | 0.79 | TNKS (0.36) | LMNAMEN1PABPC1KMT2ACYP3A4 | |
| SCHEMBL23240599 | 0.79 | TNKS (0.36) | LMNAMEN1PABPC1KMT2ACYP3A4 | |
| SCHEMBL29385770 | 0.79 | POLB (0.44) | LMNAMEN1PABPC1KMT2ATNKS | |
| SCHEMBL28671352 | 0.79 | PDE4A (0.46) | LMNAMEN1PABPC1KMT2ACYP3A4 | |
| SCHEMBL12193478 | 0.79 | POLB (0.44) | LMNAMEN1PABPC1KMT2ATNKS | |
| SCHEMBL25823793 | 0.79 | TNKS (0.36) | LMNAMEN1PABPC1KMT2ACYP3A4 | |
| SCHEMBL7608748 | 0.75 | TNKS (0.38) | LMNAMEN1PABPC1KMT2ACYP3A4 | |
| SCHEMBL5807235 | 0.74 | ALDH1A1 (0.37) | LMNAMEN1PABPC1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | claimed |
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | claimed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| CN-113039182-A | Inhibitors of YAP/TAZ-TEAD interaction and their use in cancer treatment | 伊文蒂瓦公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2021071858-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2021-04-15 | — | — | WO | disclosed |
| EP-2585462-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| CN-109641904-A | The sulphur imido acyl group purine ketone compound that 7- for treating and preventing virus infection replaces | 豪夫迈·罗氏有限公司 | 2019-04-16 | — | — | CN | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| CN-103649085-A | Pyridin-2(1h)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | ALMIRALL SA | 2014-03-19 | — | — | CN | disclosed |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-14 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-8030328-B2 | Imidazolone phenylalanine derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | TBD | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037804-A1 | Imidazolone phenylalanine derivatives | VCAM1, ICAM1, IL4I1 | LMNA 2422/4885MEN1 735/4885PABPC1 878/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | LMNA 3473/4885MEN1 380/4885PABPC1 2570/4885 |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | LMNA 3934/4885MEN1 3708/4885PABPC1 3256/4885 |
| US-20130303553-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | LMNA 4423/4885MEN1 3479/4885PABPC1 3233/4885 |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | LMNA 3934/4885MEN1 3708/4885PABPC1 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.